Dermata Therapeutics Inc (DRMA)

05:53 AM

Dermata Therapeutics Inc. Equity Warrant Stock Analysis and ForecastExceptional stock performance - Jammu Links News

05:53 AM

05:08 AM

Is Dermata Therapeutics Inc. Equity Warrant a good long term investmentExponentially increasing returns - Jammu Links News

05:08 AM

Jul 16, 2025

Dermata Therapeutics shareholders approve reverse stock split and key proposals By Investing.com - Investing.com South Africa

Jul 16, 2025

Jul 16, 2025

Dermata Therapeutics shareholders approve reverse stock split and key proposals - Investing.com

Jul 16, 2025

Jul 16, 2025

Dermata Therapeutics Holds Annual Stockholders Meeting - TipRanks

Jul 16, 2025

Jul 15, 2025

What makes Dermata Therapeutics Inc. stock price move sharplyPro Trader Stock Focus - Newser

Jul 15, 2025

Jul 15, 2025

How Dermata Therapeutics Inc. stock performs during market volatilitySecure Your Capital Strategy - Newser

Jul 15, 2025

Jul 15, 2025

What makes Dermata Therapeutics Inc. Equity Warrant stock price move sharplyFree Low-Risk Investment Plans - Newser

Jul 15, 2025

Jul 15, 2025

Why Dermata Therapeutics Inc. stock attracts strong analyst attentionExpert Backed Predictions - Newser

Jul 15, 2025

Jul 15, 2025

How Dermata Therapeutics Inc. Equity Warrant stock performs during market volatilitySecure Growth Trading Plan - Newser

Jul 15, 2025

Jul 15, 2025

Why Dermata Therapeutics Inc. Equity Warrant stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser

Jul 15, 2025

Jul 11, 2025

Dermata Therapeutics (DRMA) Stock Price, News & Analysis - MarketBeat

Jul 11, 2025

Jul 08, 2025

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis - ACCESS Newswire

Jul 08, 2025

Jul 08, 2025

Breakthrough: First-Ever Topical Botulinum Toxin for Hyperhidrosis Receives Australian Patent - Stock Titan

Jul 08, 2025

Jul 08, 2025

Dermata Therapeutics (NASDAQ:DRMA) Trading Up 4.7% – What’s Next? - Defense World

Jul 08, 2025

Jul 07, 2025

Dermata Therapeutics receives extension from Nasdaq panel to meet minimum bid price By Investing.com - Investing.com South Africa

Jul 07, 2025

Jul 07, 2025

Dermata Therapeutics receives extension from Nasdaq panel to meet minimum bid price - Investing.com

Jul 07, 2025

Jul 07, 2025

Dermata Faces Nasdaq Delisting Risk, Plans Stock Split - TipRanks

Jul 07, 2025

Jun 25, 2025

CIA(cia protocol) Tokenomics ExplainedFree Membership Group - Newser

Jun 25, 2025

Jun 04, 2025

Primary Axillary Hyperhidrosis Pipeline 2025: Groundbreaking - openPR.com

Jun 04, 2025

Jun 04, 2025

Dermata stock hits 52-week low at $0.69 amid market challenges - Investing.com India

Jun 04, 2025

Jun 04, 2025

Dermata stock hits 52-week low at $0.69 amid market challenges By Investing.com - Investing.com South Africa

Jun 04, 2025

May 30, 2025

Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Down 57.0% in May - Defense World

May 30, 2025

May 29, 2025

Dermata Therapeutics (NASDAQ:DRMA) Stock Price Down 2% – Time to Sell? - Defense World

May 29, 2025

May 23, 2025

Maxim Group Lowers Dermata Therapeutics (NASDAQ:DRMA) Price Target to $3.00 - Defense World

May 23, 2025

May 21, 2025

Dermata gears up for phase 3 trial of XYNGARI By Investing.com - Investing.com Nigeria

May 21, 2025

May 21, 2025

Maxim Group cuts Dermata Therapeutics target to $3 By Investing.com - Investing.com Nigeria

May 21, 2025

May 21, 2025

Dermata gears up for phase 3 trial of XYNGARI - Investing.com

May 21, 2025

May 21, 2025

Dermata Therapeutics Begins Manufacturing for STAR-2 Trial - TipRanks

May 21, 2025

May 21, 2025

Dermata Therapeutics IncPotential NDA Filing For Xyngari In H1 2028SEC Filing - marketscreener.com

May 21, 2025

May 21, 2025

Maxim Group cuts Dermata Therapeutics target to $3 - Investing.com

May 21, 2025

May 21, 2025

Dermata Therapeutics (DRMA) Price Target Cut Amid Capital Raise - GuruFocus

May 21, 2025

May 16, 2025

Dermata Faces Nasdaq Delisting Risk Over Bid Price - TipRanks

May 16, 2025

May 14, 2025

Dermata (DRMA) Achieves Positive Phase 3 Trial Results for Acne Treatment | DRMA Stock News - GuruFocus

May 14, 2025

May 14, 2025

DRMA: Substantial Cash Increase Enhances Financial Stability | DRMA Stock News - GuruFocus

May 14, 2025

May 14, 2025

Dermata Reports Positive Phase 3 Trial Results - TipRanks

May 14, 2025

May 14, 2025

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - ACCESS Newswire

May 14, 2025

May 14, 2025

Dermata Therapeutics, Inc. SEC 10-Q Report - TradingView

May 14, 2025

May 03, 2025

Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering - ACCESS Newswire

May 03, 2025

Apr 28, 2025

Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks - ACCESS Newswire

Apr 28, 2025

Apr 26, 2025

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024 - ACCESS Newswire

Apr 26, 2025